The Goldman Sachs Group Raises Gilead Sciences (NASDAQ:GILD) Price Target to $108.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by equities research analysts at The Goldman Sachs Group from $105.00 to $108.00 in a report released on Friday,MarketScreener reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective would suggest a potential downside of 12.06% from the stock’s current price.

GILD has been the subject of a number of other reports. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Citigroup lifted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.17.

Gilead Sciences Stock Up 4.2%

Shares of NASDAQ:GILD opened at $122.81 on Friday. The firm has a fifty day moving average price of $115.22 and a two-hundred day moving average price of $110.52. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a one year low of $85.60 and a one year high of $124.11. The company has a market cap of $152.38 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm earned $2.01 EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock valued at $8,281,540 over the last three months. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at about $25,000. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the second quarter valued at about $27,000. Finally, Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at about $29,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.